#NephMadness 2023: IgA Nephropathy Region
Submit your picks! | NephMadness 2023 | #NephMadness | #IgAN Selection Committee Member: Dana Rizk @DanaRizk1 Dana Rizk is Professor of Medicine in
Submit your picks! | NephMadness 2023 | #NephMadness | #IgAN Selection Committee Member: Dana Rizk @DanaRizk1 Dana Rizk is Professor of Medicine in
AstraZeneca wins EU backing for heart drug, but suffers lung cancer setback By Natalie Grover and Sinchita Mitra Dec 19 (Reuters) –
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are an emerging class of medications that have become increasingly popular in medication regimens
Sodium/glucose cotransporter 2 inhibitors (SGLT2i / gliflozins) are a novel class of medications which act by inhibiting the SGLT2 transporter
SGLT2 inhibitors for CKD, Turmeric for knee pain and Honey for URTI. Summary Time for spooky cakes with a side of candy corn. We discuss
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness
Alexion Pharmacueticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness
Alexion Pharmacueticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness
Alexion Pharmacueticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness
For the first time, an oral add-on treatment, Dapagliflozin (aka Forxiga from Astra Zeneca) has received regulatory approval for managing type 1
For the first time, an oral add-on treatment, Dapagliflozin (aka Forxiga from Astra Zeneca) has received regulatory approval for managing type 1